Scleroderma is an autoimmune disease which causes hardening of the skin. This can result in a loss of mobility, and in some extreme cases can affect internal organs. Scleroderma.org functions as a sounding board for patients and carers to share their own experiences with the disease. 1. Amanda’s Story…
Sine sclerosis, which is also known as sine scleroderma or systemic sclerosis sine scleroderma (ssSSc), is an extremely rare type of scleroderma. MORE: Research is the focus of Rare Disease Day 2017 Unlike “regular” scleroderma, in sine sclerosis the buildup of fibrosis occurs not on the skin but in one or more internal organs,…
In honor of Scleroderma Awareness Month, we’re sharing some of our favourite scleroderma books. 1. “The Scleroderma Book: A Guide for Patients and Families” by Maureen D. Mayes This is the book to…
Scleroderma is a condition that causes hardening of the skin and, in some cases, some organs in the body. Although the medical term we use to describe the condition was only coined in the early 19th century, scleroderma is a condition with a long history. According to news-medical.net, there are records of its symptoms…
Today is the World Scleroderma Day, and to mark the occasion the Scleroderma Foundation is hosting a virtual “stepping out to cure scleroderma” walk-a-thon. The online initiative is an opportunity to connect with friends, family and supporters, and take part in an event to honor — or in memory of…
Scleroderma is normally classified as an autoimmune rheumatic disease. According to scleroderma.org, the name of the disease itself comes from the Greek language: sclero meaning “hard” and “derma” meaning skin. Together, they describe one of the most visible symptoms of the disease: the hardening of the skin. Scleroderma is a chronic connective tissue…
Soin Neuroscience recently submitted an orphan drug application to the U.S. Food and Drug Administration (FDA) for the company’s investigational drug TV1001SR (sodium nitrite), being developed for the treatment of scleroderma. Several completed clinical and preclinical trials have demonstrated TV1001SR enhances the growth of small arteries and promote blood flow. This…
Cytori Therapeutics recently completed all 48-week follow-up visits in its STAR trial evaluating adipose-derived regenerative cells (ADRCs) for the treatment of patients with scleroderma-caused hand dysfunction. A total of 88 participants were enrolled, and the last patient’s 48-week visit was conducted earlier this week, the company said in a press…
Registration is open for the Scleroderma Foundation‘s 2017 National Patient Education Conference, July 21-23 in the Phoenix suburb of Chandler, Arizona. The conference will focus on helping patients, family members, caregivers, and others learn about therapies, manage the disease better, cope with the emotional challenges of scleroderma, stay motivated against the…
Corbus Pharmaceuticals of Norwood, Mass., will commence a single Phase 3 clinical trial evaluating Anabasum (formerly known as Resunab or JBT-101) to treat diffuse cutaneous systemic sclerosis (SSc). This new study — which will support a New Drug Application (NDA) — is based on guidance provided by the U.S. Food and Drug…
Get regular updates to your inbox.